As part of an international team, led by HepaRegeniX, ZoBio solved the structure of an inhibitor bound to the kinase MKK4 using a non-classical approach to structural…
Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2:KRAS PPI Inhibitors
The recent publication in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important…
Oncodesign Services Acquires ZoBio
We are excited to announce that ZoBio will join forces with Oncodesign Services (ODS), a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services with notable expertise in oncology and immuno-inflammation.
https://www.oncodesign-services.com/
ZoBio is a Crystallography Company (Too)
Many still think of ZoBio as an NMR company. And while NMR will always have a special place in our hearts, we also have a thriving crystallography team!
Detailed and timely structural information is a cornerstone of rational drug design and X-ray crystallography plays a key role in most…